Haemonetics Corporation: Business Overview, Financials & Competitive Analysis
Haemonetics Corporation scores 7/10 on the AskCyborg Cyborg Score (Strong). Strong margin expansion and 35% earnings growth, trading at significant discount to fair value with manageable leverage in a high P/E comparables environment. Over the last 12 months, Haemonetics converted $1.3B of revenue into $175.4M of net income with a 13.3% net margin (vs. 9.5% prior year), with 35% year-over-year.
What is Haemonetics Corporation's industry? Haemonetics Corporation (haemonetics.com) operates in Medical Technology / Hospital Equipment & Supplies. AskCyborg classifies Haemonetics Corporation under Medical Technology / Hospital Equipment & Supplies in its company registry.
Haemonetics Corporation is a medical technology company providing a suite of hospital technologies solutions in the United States and internationally. Its solutions address critical medical needs including hospital te...
Cyborg Score thesis
Strong margin expansion and 35% earnings growth, trading at significant discount to fair value with manageable leverage in a high...
Read the full analyst-debate transcript →Get the Latest Haemonetics Corporation Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeHaemonetics Corporation Overview
Pro stress-test →Haemonetics Corporation is a medical technology company providing a suite of hospital technologies solutions in the United States and internationally. Its solutions address critical medical needs including hospital technologies designed to advance standards of care, end-to-end plasma collection technologies for plasma centers, and products enabling blood centers to collect in-demand blood components.
Strategic Profile
Pro stress-test →Technology-driven recurring revenue streams and market share gains are positioning Haemonetics for sustainable margin expansion and robust earnings growth, with international expansion and secular health trends expected to drive long-term demand supporting multi-year revenue acceleration. At a share price of $59.34, the company trades on a trailing P/E of 15.7x versus peers at 32.6x and the wider US Medical Equipment group at 30.7x.
Competitive Landscape
Pro stress-test →Haemonetics is covered by 27 analysts and operates in the medical technology space competing against established players in blood management, plasma collection, hospital technologies, and vascular intervention products. The company's valuation (15.7x P/E) is substantially below peer group average (32.6x) and medical equipment industry average (30.7x), suggesting potential mispricing or specific risk concerns in the market.
Industry Context
Haemonetics Corporation operates in Medical Technology / Hospital Equipment & Supplies.
Key facts
Founded: 1971 · Headquarters: Boston, Massachusetts · Revenue: $1.30B · Market cap: $2.98B